Eversept Partners, LP holds a focused book of 104 stocks worth $1.5B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Welltower Inc and trimmed GSK PLC-Spon ADR. Their largest long position is United Therapeutics Corp at 10% of the equity book. They also disclosed $289.9M in put options (a bearish bet) and $89.0M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1697013/holdings"
Use Arkolith to show Eversept Partners, LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | United Therapeutics Corp Del COM | $156.7M | 264.3K | 10.3% | ▲+4.6% Added · +12K sh | |
| 2 | Abivax Sa SPONSORED ADS | $104.0M | 934.4K | 6.9% | ▲+42% Added · +277K sh | |
| 3 | GSK PLC SPONSORED ADR | $98.5M | 1.79M | 6.5% | ▼−33% Reduced · −895K sh | |
| 4 | Vera Therapeutics Inc CL A | $87.4M | 2.17M | 5.8% | ▼−29% Reduced · −899K sh | |
| 5 | Natera Inc COM | $76.9M | 384.7K | 5.1% | ▲+15% Added · +50K sh | |
| 6 | Syndax Pharmaceuticals Inc COM | $67.4M | 2.89M | 4.4% | ▼−13% Reduced · −429K sh | |
| 7 | Celldex Therapeutics Inc New COM NEW | $56.7M | 1.79M | 3.7% | ▲+25% Added · +353K sh | |
| 8 | Vaxcyte Inc COM | $53.7M | 924.2K | 3.5% | ▼−23% Reduced · −274K sh | |
| 9 | Brookdale SR Living Inc COM | $48.8M | 3.57M | 3.2% | ▲+852% Added · +3.2M sh | |
| 10 | Ionis Pharmaceuticals Inc COM | $47.5M | 632.1K | 3.1% | ▲+17% Added · +94K sh | |
| 11 | Hca Healthcare Inc COM | $37.5M | 79.2K | 2.5% | ▼−17% Reduced · −17K sh | |
| 12 | Welltower Inc COM | $35.8M | 181.0K | 2.4% | ▲New New position | |
| 13 | Healthpeak Properties Inc COM | $32.5M | 1.98M | 2.1% | ▲New New position | |
| 14 | Insulet Corp COM | $30.1M | 143.5K | 2.0% | ▲+92% Added · +69K sh | |
| 15 | Biocryst Pharmaceuticals Inc COM | $28.9M | 3.04M | 1.9% | ▲+1.6% Added · +47K sh | |
| 16 | Geron Corp COM | $28.1M | 18.83M | 1.8% | ▲+6.7% Added · +1.2M sh | |
| 17 | Omega Healthcare Invs Inc COM | $25.7M | 585.7K | 1.7% | ▲New New position | |
| 18 | Liquidia Corporation COM NEW | $25.6M | 677.4K | 1.7% | ▲+33% Added · +168K sh | |
| 19 | Community Health Sys Inc New COM | $25.5M | 8.68M | 1.7% | ▲+9.2% Added · +733K sh | |
| 20 | Avantor Inc COM | $23.3M | 2.97M | 1.5% | ▼−6.4% Reduced · −202K sh | |
| 21 | Qiagen NV ORD SHARES | $21.8M | 545.3K | 1.4% | ▲New New position | |
| 22 | Encompass Health Corp COM | $18.8M | 194.1K | 1.2% | ▲+82% Added · +87K sh | |
| 23 | Eli Lilly & Co COM | $17.5M | 19.0K | 1.2% | ▲+79% Added · +8K sh | |
| 24 | Travere Therapeutics Inc COM | $16.1M | 542.6K | 1.1% | ▼−54% Reduced · −632K sh | |
| 25 | Cytomx Therapeutics Inc. COM | $15.0M | 3.19M | 1.0% | ▲+27% Added · +681K sh | |
| 26 | Repligen Corp COM | $14.2M | 120.8K | 0.9% | ▲New New position | |
| 27 | Beta Bionics Inc COM | $14.2M | 1.41M | 0.9% | ▲+109% Added · +737K sh | |
| 28 | Viridian Therapeutics Inc COM | $14.0M | 713.3K | 0.9% | ▼−60% Reduced · −1.1M sh | |
| 29 | Arcutis Biotherapeutics Inc COM | $13.6M | 576.6K | 0.9% | ▲+33% Added · +142K sh | |
| 30 | Ardelyx Inc COM | $13.4M | 2.23M | 0.9% | ▲+30% Added · +514K sh | |
| 31 | LTC Pptys Inc COM | $11.9M | 321.0K | 0.8% | ▲New New position | |
| 32 | Biomarin Pharmaceutical Inc COM | $11.7M | 207.8K | 0.8% | ▲+122% Added · +114K sh | |
| 33 | Chemed Corp New COM | $11.7M | 31.1K | 0.8% | ▲New New position | |
| 34 | Pharvaris N V COM | $11.5M | 407.0K | 0.8% | ▼−7.3% Reduced · −32K sh | |
| 35 | Pennant Group Inc COM | $9.5M | 312.2K | 0.6% | ▲+6.2% Added · +18K sh | |
| 36 | Newamsterdam Pharma Company ORDINARY SHARES | $9.1M | 285.8K | 0.6% | ▼−32% Reduced · −135K sh | |
| 37 | Palisade Bio Inc COM | $8.7M | 4.99M | 0.6% | ▼−7.5% Reduced · −404K sh | |
| 38 | Moderna Inc COM | $8.1M | 159.7K | 0.5% | ▼−40% Reduced · −108K sh | |
| 39 | Viking Therapeutics Inc COM | $7.8M | 239.1K | 0.5% | ▲New New position | |
| 40 | Icon PLC SHS | $7.6M | 68.7K | 0.5% | ▼−28% Reduced · −27K sh | |
| 41 | Xenon Pharmaceuticals Inc COM | $7.5M | 129.6K | 0.5% | ▼−44% Reduced · −102K sh | |
| 42 | Revvity Inc COM | $7.4M | 84.9K | 0.5% | ▼−48% Reduced · −78K sh | |
| 43 | Agios Pharmaceuticals Inc COM | $6.8M | 200.0K | 0.4% | ▲New New position | |
| 44 | Structure Therapeutics Inc SPONSORED ADS | $6.7M | 138.0K | 0.4% | ▲+8.2% Added · +10K sh | |
| 45 | Bio-Techne Corp COM | $6.6M | 125.9K | 0.4% | ▼−67% Reduced · −252K sh | |
| 46 | Glaukos Corp COM | $6.5M | 60.2K | 0.4% | ▼−59% Reduced · −87K sh | |
| 47 | Tenet Healthcare Corp COM NEW | $5.6M | 29.5K | 0.4% | ▲New New position | |
| 48 | Madrigal Pharmaceuticals Inc COM | $5.2M | 10.0K | 0.3% | ▲New New position | |
| 49 | Intuitive Surgical Inc COM NEW | $5.1M | 11.1K | 0.3% | ▼−38% Reduced · −7K sh | |
| 50 | Esperion Therapeutics Inc Ne COM | $4.8M | 1.74M | 0.3% | ▼−55% Reduced · −2.1M sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | INVESCO QQQ TRUST SERIES 1QQQ | $137.8M | 239K |
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $69.6M | 107K |
| CALL · bullish | VERTEX PHARMACEUTICALS INCVRTX | $40.2M | 90K |
| PUT · bearish | ISHARES 20+ YEAR TREASURY BDTLT | $37.2M | 429K |
| CALL · bullish | QIAGEN N.V.QGEN | $19.1M | 476K |
| CALL · bullish | INSMED INCINSM | $15.4M | 94K |
| PUT · bearish | ISHR IBX USD HIYLD CB ETF-UIHYG | $14.3M | 180K |
| CALL · bullish | UNITEDHEALTH GROUP INCUNH | $10.8M | 40K |
| PUT · bearish | ISHARES RUSSELL 2000 ETFIWM | $9.9M | 40K |
| PUT · bearish | SS TECHNOLOGY SELECT SECTORXLK | $9.3M | 70K |
| PUT · bearish | PRAXIS PRECISION MEDICINES IPRAX | $4.8M | 15K |
| PUT · bearish | SS SPDR S&P BIOTECH ETFXBI | $3.8M | 30K |
| PUT · bearish | UNIVERSAL HEALTH SERVICES-BUHS | $3.3M | 18K |
| CALL · bullish | SS ENERGY SELECT SECTORXLE | $3.1M | 50K |
| CALL · bullish | REPLIMUNE GROUP INCREPL | $398K | 52K |
| CALL · bullish | KARYOPHARM THERAPEUTICS INCKPTI | $133K | 24K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 120 | $1.9B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 107 | $2.0B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 86 | $1.5B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 68 | $1.1B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 57 | $984.7M | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 65 | $1.1B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 67 | $1.5B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 74 | $1.5B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 70 | $1.5B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 57 | $1.1B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 69 | $1.2B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Nov 8, 2023 | 71 | $1.2B | 13F-HR/A |
| Q1 2023 | Mar 31, 2023 | Nov 8, 2023 | 62 | $1.4B | 13F-HR/A |
| Q4 2022 | Dec 31, 2022 | Nov 8, 2023 | 68 | $1.1B | 13F-HR/A |
| Q3 2022 | Sep 30, 2022 | Nov 8, 2023 | 70 | $1.8B | 13F-HR/A |
| Q2 2022 | Jun 30, 2022 | Nov 8, 2023 | 77 | $1.4B | 13F-HR/A |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.